CO6260060A2 - 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos - Google Patents
2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativosInfo
- Publication number
- CO6260060A2 CO6260060A2 CO10033946A CO10033946A CO6260060A2 CO 6260060 A2 CO6260060 A2 CO 6260060A2 CO 10033946 A CO10033946 A CO 10033946A CO 10033946 A CO10033946 A CO 10033946A CO 6260060 A2 CO6260060 A2 CO 6260060A2
- Authority
- CO
- Colombia
- Prior art keywords
- 3alkyl
- cyclopropyl
- optionally substituted
- fluoro
- cyano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
1.- Un compuesto de fórmula (I):donde:R1 se selecciona entre C1-4alquilo, ciclopropilo, ciclopropilmetilo y ciclobutilo; donde dicho ciclopropilo puede estar opcionalmente sustituido por metilo; y donde R1 puede estar opcionalmente sustituido por uno o más R5; m es 0 ó 1; R2 se selecciona entre C1-6alquilo, C2-6alquenilo, C2-6alquinilo, C3-6cicloalquilo, ciclopentenilo, ciclohexenilo, oxetanilo, tetrahidropiranilo, tetrahidrofuranilo, oxepanilo, azetidinilo, pirrolidinilo, piperidinilo y azepanilo; donde R2 puede estar opcionalmente sustituido en un carbono por uno o más R6; y donde si R2 contiene un resto -NH- en el anillo, dicho nitrógeno puede estar opcionalmente sustituido por R7;R3 se selecciona independientemente entre fluoro, cloro, bromo, ciano, metoxi, etoxi, trifluorometoxi, metilo, etilo, trifluorometilo, etenilo, etinilo, ciclopropilo, metiltio, etiltio, N-metilamino, N,N-dimetilamino, amino y metilsulfoniloxi; n es un número entero seleccionado entre 0 y 3; donde los valores de R3 pueden ser los mismos o diferentes; R4 es -L-R8 o R9; L se selecciona entre etinileno, etenileno, ciclopropilo y -X-C1-2alquileno-; donde X es un enlace directo, -O, -S-, -NH-, -OS(O)2-, -N(CH3)- o -N(CH2R10)-; y donde L puede estar opcionalmente sustituido en un carbono por uno o más fluoro; R5 es ciano o fluoro; R6 se selecciona entre C1-3alquilo, C1-3alcoxi, N-(C1-3alquil)amino, N,N-(C1-3alquil)2amino, hidroxi, amino, fluoro y ciano; R7 se selecciona entre C1-3alquilo, ciclopropilo, C1-3alcanoílo y C1-3alquilsulfonilo;R8 y R10 se seleccionan cada uno independientemente entre cloro, bromo, yodo, ciano, ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95750807P | 2007-08-23 | 2007-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260060A2 true CO6260060A2 (es) | 2011-03-22 |
Family
ID=39951669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10033946A CO6260060A2 (es) | 2007-08-23 | 2010-03-23 | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110118238A1 (es) |
| EP (1) | EP2212326A1 (es) |
| JP (1) | JP2010536841A (es) |
| KR (1) | KR20100057650A (es) |
| CN (1) | CN103298814A (es) |
| AU (1) | AU2008290330A1 (es) |
| BR (1) | BRPI0815709A2 (es) |
| CA (1) | CA2696200A1 (es) |
| CO (1) | CO6260060A2 (es) |
| CR (1) | CR11295A (es) |
| DO (1) | DOP2010000064A (es) |
| EA (1) | EA201000341A1 (es) |
| EC (1) | ECSP10010034A (es) |
| MX (1) | MX2010002115A (es) |
| NI (1) | NI201000032A (es) |
| NZ (1) | NZ584138A (es) |
| SV (1) | SV2010003491A (es) |
| WO (1) | WO2009024824A1 (es) |
| ZA (1) | ZA201001193B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| EP2343295A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| FR2955109B1 (fr) | 2010-01-08 | 2012-09-07 | Sanofi Aventis | Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique |
| UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| UY33539A (es) * | 2010-08-02 | 2012-02-29 | Astrazeneca Ab | Compuestos químicos alk |
| CA2821819A1 (en) * | 2010-12-17 | 2012-06-21 | Marcus Koppitz | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CN103415518A (zh) * | 2010-12-17 | 2013-11-27 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪 |
| EP2651944B1 (en) * | 2010-12-17 | 2015-09-23 | Bayer Intellectual Property GmbH | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| US9212184B2 (en) * | 2010-12-17 | 2015-12-15 | Bayer Intellectual Property Gmbh | 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors |
| EP2651950A1 (en) * | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CN103370322B (zh) * | 2010-12-17 | 2016-02-10 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 |
| US20140120087A1 (en) | 2011-04-21 | 2014-05-01 | Bayer Intellectual Property Gmbh | Triazolopyridines |
| WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
| UA112096C2 (uk) | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| ES2605946T3 (es) | 2012-03-14 | 2017-03-17 | Bayer Intellectual Property Gmbh | Imidazopiridazinas sustituidas |
| AP3778A (en) | 2012-07-10 | 2016-08-31 | Bayer Pharma AG | Method for preparing substituted triazolopyridines |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| US9670202B2 (en) * | 2013-06-07 | 2017-06-06 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines |
| CN105377848A (zh) | 2013-06-11 | 2016-03-02 | 拜耳制药股份公司 | 取代的三唑并吡啶的前体药物衍生物 |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| PL3283642T3 (pl) | 2015-04-17 | 2024-04-22 | Crossfire Oncology Holding B.V. | Biomarkery prognostyczne dla chemioterapii inhibitorem TTK |
| MY183036A (en) | 2016-12-20 | 2021-02-08 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
| JP7047772B2 (ja) * | 2016-12-21 | 2022-04-05 | 小野薬品工業株式会社 | Ｂｒｋ阻害化合物 |
| TWI820146B (zh) | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| EP4137491A4 (en) * | 2020-04-17 | 2024-05-08 | Chengdu Baiyu Pharmaceutical Co Ltd | IMIDAZOLINONE DERIVATIVE AND ITS USE IN MEDICINE |
| KR102409595B1 (ko) * | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체 |
| CZ309356B6 (cs) * | 2020-09-15 | 2022-09-28 | Ústav experimentální botaniky AV ČR, v. v. i | Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty |
| WO2022135360A1 (zh) * | 2020-12-21 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
| CN116917288A (zh) * | 2021-03-22 | 2023-10-20 | 成都赜灵生物医药科技有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
| CN117321057A (zh) * | 2021-08-23 | 2023-12-29 | 成都百裕制药股份有限公司 | 一种咪唑啉酮衍生物的制备工艺及其中间体 |
| WO2023046072A1 (zh) * | 2021-09-23 | 2023-03-30 | 成都百裕制药股份有限公司 | 咪唑啉酮衍生物的晶型 |
| TW202402282A (zh) * | 2022-07-13 | 2024-01-16 | 大陸商成都百裕製藥股份有限公司 | 咪唑啉酮衍生物在製備用於聯合放療治療腫瘤的藥物中的應用 |
| WO2024017220A1 (zh) * | 2022-07-20 | 2024-01-25 | 成都百裕制药股份有限公司 | 咪唑啉酮衍生物联合多柔比星在治疗肿瘤中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947695B2 (en) * | 2005-01-14 | 2011-05-24 | Janssen Pharmaceutica Nv | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| WO2006091737A1 (en) * | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| JO3235B1 (ar) * | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
-
2008
- 2008-08-20 JP JP2010521487A patent/JP2010536841A/ja active Pending
- 2008-08-20 EA EA201000341A patent/EA201000341A1/ru unknown
- 2008-08-20 AU AU2008290330A patent/AU2008290330A1/en not_active Abandoned
- 2008-08-20 EP EP08788695A patent/EP2212326A1/en not_active Withdrawn
- 2008-08-20 WO PCT/GB2008/050724 patent/WO2009024824A1/en active Application Filing
- 2008-08-20 BR BRPI0815709A patent/BRPI0815709A2/pt not_active IP Right Cessation
- 2008-08-20 MX MX2010002115A patent/MX2010002115A/es not_active Application Discontinuation
- 2008-08-20 CA CA2696200A patent/CA2696200A1/en not_active Abandoned
- 2008-08-20 CN CN200880113474XA patent/CN103298814A/zh active Pending
- 2008-08-20 KR KR1020107006059A patent/KR20100057650A/ko not_active Application Discontinuation
- 2008-08-20 US US12/674,749 patent/US20110118238A1/en not_active Abandoned
- 2008-08-20 NZ NZ584138A patent/NZ584138A/en not_active IP Right Cessation
-
2010
- 2010-02-18 ZA ZA201001193A patent/ZA201001193B/xx unknown
- 2010-02-23 NI NI201000032A patent/NI201000032A/es unknown
- 2010-02-23 CR CR11295A patent/CR11295A/es not_active Application Discontinuation
- 2010-02-23 DO DO2010000064A patent/DOP2010000064A/es unknown
- 2010-02-23 SV SV2010003491A patent/SV2010003491A/es not_active Application Discontinuation
- 2010-03-12 EC EC2010010034A patent/ECSP10010034A/es unknown
- 2010-03-23 CO CO10033946A patent/CO6260060A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2010000064A (es) | 2010-03-31 |
| KR20100057650A (ko) | 2010-05-31 |
| JP2010536841A (ja) | 2010-12-02 |
| CN103298814A (zh) | 2013-09-11 |
| SV2010003491A (es) | 2010-07-06 |
| WO2009024824A1 (en) | 2009-02-26 |
| BRPI0815709A2 (pt) | 2017-06-13 |
| EA201000341A1 (ru) | 2010-10-29 |
| US20110118238A1 (en) | 2011-05-19 |
| ECSP10010034A (es) | 2010-04-30 |
| CR11295A (es) | 2010-05-28 |
| AU2008290330A1 (en) | 2009-02-26 |
| NZ584138A (en) | 2011-10-28 |
| CA2696200A1 (en) | 2009-02-26 |
| MX2010002115A (es) | 2010-06-01 |
| NI201000032A (es) | 2010-12-07 |
| ZA201001193B (en) | 2010-10-27 |
| EP2212326A1 (en) | 2010-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6260060A2 (es) | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| PE20210163A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| PE20190711A1 (es) | N-(fenils ulfonil) benzamidas y compuestos relacionados como inhibidores de bcl-2 | |
| UY28150A1 (es) | Agentes terapeuticos | |
| PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
| UY29316A1 (es) | Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos. | |
| WO2008057855A9 (en) | Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| AR054186A1 (es) | Derivados de tetrahidroindazolona y tetrahidroindolona | |
| NI201000013A (es) | Sulfonamidas como moduladores del trpm8 | |
| NI200700156A (es) | Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurológicos | |
| PE20141110A1 (es) | Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos | |
| PE20130647A1 (es) | Indoles | |
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| PE20060241A1 (es) | 2-quinolil-oxazoles sustituidos como inhibidores de pde4 | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| BRPI0814382A2 (pt) | Composto, uso do composto, e, composição farmacêutica | |
| PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
| PE20070833A1 (es) | Compuestos de pirimidinil benzotiofeno | |
| UY28855A1 (es) | Derivados de la 1-amino-ftalazina su preparación y su uso en terapia | |
| PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
| AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
| PE20071311A1 (es) | Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |